Vitamin D levels in Egyptian HCV patients (Genotype 4) treated with pegylated interferon

Acta Gastro-Enterologica Belgica

Volumn 76, Issue 1, 2013, Pages 38-44

  Mohamed, A A ^a   Sabry, Nirmeen A ^b   Abbassi, M M ^b   Ibrahim, W A ^c   Ali Eldin, Z A ^c  

^a Biochemistry Department   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Egyptian patient; Genotype 4; HCV; Vitamin D

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VITAMIN D;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER FUNCTION; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG MONITORING; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; VITAMIN D; YOUNG ADULT;

EID: 84875204856     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. HATHCOCK J.N., SHAO A., VIETH R., HEANEY R. Risk assessment for vitamin D. Am. J. Clin. Nutr., 2007, 85 (1): 6-18.
2. BAEKE F., TAKIISHI T., KORF H., GYSEMANS C., MATHIEU C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol., 2010, 10 (4): 482-496
3. LOPICCOLO M.C., LIM H.W. Vitamin D in health and disease. Photodermatol. Photoimmunol. Photomed., 2010, 26 (5): 224-229.
4. NORMAN A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am. J. Clin. Nutr., 2008, 88 (2): 491S-499S.
5. CHIU K., CHU A., GO V., SAAD M. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr., 2004, 79 (5): 820-825.
6. HOLICK M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr., 2004, 79 (3): 362-371.
7. BOUILLON R., AUWERX J., DEKEYSER L., FEVERY J., LISSENS W., DE MOOR P. Serum vitamin D metabolites and their binding-protein in patients with liver cirrhosis. J. Clin. Endocrinol. Metab., 1984, 59 (1): 86-89.
8. MONEGAL A., NAVASA M., GUANABENS N., PERIS P., PONS F., MARTINEZ DE OSABA M.J. et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif. Tissue Int., 1997, 60 (2): 148-154.
9. TSUNEOKA K., TAMEDA Y., TAKASE K., NAKANO T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J. Gastroenterol., 1996, 31 (5): 669-678.
10. HOLICK M.F. Vitamin D deficiency. N. Eng. J. Med., 2007, 357 (3): 266-281.
11. GEORGEL P., SCHUSTER C., ZEISEL M., STOLL-KELLER F., BERG T., BAHRAM S. et al. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol. Med., 2010, 16 (6): 277-286.
12. ADAM R., MC MASTER P., O'GRADY J.G., GASTAING D., KLEMPNAUER J.L., JAMIESON N. et al. Evolution of liver transplantation in Europe: Report of the European liver transplant registry. Liver Transpl., 2003, 9 (12): 1231-1243.
13. GOLDMAN R., RESSO M., H.W., ABDEL-HAMID M., GOLDMAN L., WANG A., VARGHESE R.S. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis, 2007, 28 (10): 2149-2153.
14. ARTHUR R.R., HASSAN N.F., ABDELLAH M.Y., EL-SHARKAWY M.S., SAAD M.D., HACKBART B.G. et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. T. Roy. Soc. Trop. Med. H., 1997, 91 (3): 271-274.
15. ZAYADI A.R., SELIM O., IBRAHIM E.H., HAMDY H., DABBOUS H., AHDY A. et al. Does schistosomiasis play a role in the high seroprevalence of HCV antibody among Egyptians? Trop. gastroenterol., 1997, 18 (3): 98-100.
16. HABIB M., MOHAMED M.K., ABDEL AZIZ F., MAGDER L.S., ABDEL HAMID M., GAMIL F. et al. Hepatitis C virus infection in a community in the Nile Delta: Risk factors for seropositivity. Hepatology, 2001, 33 (1): 248-253.
17. NAFEH M.A., MEDHAT A., SHEHATA M., MIKHAIL N.N., SWIFEE Y., ABDEL-HAMID M. et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am. J. Trop. Med. Hyg., 2000, 63 (5-6): 236-241.
18. HASSAN M.M., ZAGHLOUL A.S., EL-SERAG H.B., SOLIMAN O., PATT Y.Z., CHAPPELL C.L. et al. The role of hepatitis C in hepatocellular carcinoma: a casecontrol study among Egyptian patients. J. Clin. Gastroenterol., 2001, 33 (2): 123-126.
19. ALTER M.J., KRUSZON-MORAN D., NAINAN O.V., MCQUILLAN G.M., GAO F., MOYER L.A. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med., 1999, 341 (8): 556-562.
20. RAY S.C., ARTHUR R.R., CARELLA A., BUKH J., THOMAS D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect Dis., 2000, 182 (3): 698-707.
21. BITETTO D., FATTOYICH G., FABRIS C., CERIANI E., FALLETI E., FORNASIERE E. et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology, 2011, 53 (4): 1118-1126.
22. LOPEZ-ALONSO G., ÁGEDA M., DEVESA M.J., CUENCA F., SUÁREZ A., ORTEGA L. et al. Results of the treatment of chronic hepatitis C genotype 4. A comparative analysis with genotype 1. Rev. Esp. De Enferm Dig., 2008, 100 (4): 208-211.
23. Declaration of Helsinki. World Medical Association. Available from http://www.wma.net/en/30publications/10policies/b3/ (Accessed August, 2011)
24. ISHAK K., BAPTISTA A., BIANCHI L. et al. Histological grading and staging of chronic hepatitis. J. Hepatol., 1995, 22: 696-699.
25. KNODELL R.G., ISHAK K.G., BLACK W.C., CHEN T.S., CRAIG R., KAPLOWITZ N. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981, 1 (5): 431-435.
26. ARTEH J., NARRA S., NAIR S. Prevalence of vitamin D deficiency in chronic liver disease. Dig. Dis. Sci., 2010, 55 (9): 2624-2628.
27. PETTA S., CAMMA C., SCAZZONE C., TRIPODO C., DIMARCO G., BONO A. et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51 (4): 1158-1167.
28. LANGE CM., BOJUNGA J., RAMOS-LOPEZ E., VON WAGNER M., HASSLER A., VERMEHREN J. et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol., 2011, 54 (5): 887-893.
29. TERRIER B., CARRAT F., GERI G., POL S., PIROTH L., HALFON P. et al. Low 25-OH vitamin D serum levels correlate with severe fibrosisin HIV-HCV co-infected patients with chronic hepatitis. J. Hepatol., 2011, 55 (4): 756-761.
30. GAL-TANAMY M., BACHMETOV L., RAVID A., KOREN R., ERMAN A., TUR-KASPA R. et al. Vitamin D: An Innate Antiviral Agent Suppressing Hepatitis C Virus in Human Hepatocytes. Hepatology, 2011, 54 (5): 1570-1579.
31. CONESA-BOTELLA A., FLORENCE E., LYNEN L., COLEBUNDERS R., MENTEN J., MORENO-REYES R. Decrease of vitamin D concentration in patients with HIV infection on a non-nucleoside reverse transcriptase inhibitor-containing regimen. RAIDS Res. Ther., 2010, 23: 7-40.
32. GOMBAT A.F., BORREGARD N., KOEFFLER H.P. Human cathelicdin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor is strongly upregulated in myeloid cells by 1,25-dihydroxvitamin D3. FASEB J., 2005, 19: 1067-1077.
33. BALS R., WILSON J.M. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci., 2003, 60: 711-720.
34. ASSY N., ABU-MOUCH S. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J. Gastroenterol., 2012, 18 (8): 800-805.
35. BRESSLER B.L., GUINDI M., TOMLINSON G., HEATHCOTE J. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatitis C. Hepatology, 2003, 38 (3): 639-644.
36. PATTULLO V., RAVINDRAN N.C., MAZZULLI T. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. J. Viral. Hepat., 2010, 17 (12): 834-838.
37. EL-ZANATY F., WAY A. Egypt Demographic and Health Survey, 2009, Ministry of Health. El-Zanaty and Associates, and Macro International. http://pdf.usaid.gov/pdf_docs/PNADO806.pdf (Accessed April, 2012)
38. ABU-MOUCH S., FIREMAN Z., JARCHOVSKY J., ZEINA A., ASSY N. Vitamin D supplementation improves sustained virology response in chronic hepatitis C (genotype 1)-naive patients. World J. Gastroenterol., 2011, 17 (47): 5184-5190.
39. BITETTO D., FABRIS C., FORNASIERE E., PIPAN C., FUMOLO E., CUSSIGH A. et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl. Int., 2011, 24 (1): 43-50.